Healthcare Sector Stock Alert for Osteotech Inc. Issued by Beacon Equity

DALLAS, Jan. 15, 2010 (GLOBE NEWSWIRE) — announces an investment report featuring medical products maker Osteotech Inc. (Nasdaq:OSTE). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at:

Get our alerts BEFORE the rest of the market. Follow us on Twitter:

Osteotech Inc. (OSTE), a medical technology company, develops, processes and distributes biologic products focused on the orthopedic, neurosurgical and oral/maxillofacial surgery markets. The Company is focused on creating technology platforms that provides a variety of procedural specific biologic products to address the changing needs of orthopedics and healthcare in general. The Company’s products focus on biologic solutions for regenerative medicine that can alleviate pain, promote healing and restore functions. OSTE operates in five segments: Demineralized Bone Matrix (DBM), Hybrid/Synthetic, Traditional Tissue, Spinal Allograft, and Human Collagen Technology.

In the report, the analyst notes:

“In its preliminary results for the fourth quarter of 2009, OSTE reported revenue growth of about 7% in the said quarter, citing sales of recently launched bone graft and fusion products. The Company recorded about $400,000 in revenue from its MagniFuse spinal graft products, which reached the market in October, and $200,000 from its FacetLinx fusion system, which was launched in the third quarter.

“For the full year 2009, the Company said it expects $96.7 million in revenue, or $93.4 million excluding the license revenue. It previously expected $92 million to $94 million. OSTE also said it exited 2009 with approximately $10.7 million in cash, above the range of $9 million to $10 million it had expected.”

To read the entire report visit:

See what investors are saying about OSTE at penny stock forum. is one of the industry’s largest small-cap report providers striving to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon research, please visit

Beacon Equity Disclosure

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

CONTACT:  Beacon Equity Research
          Jeff Bishop


Josh Sandberg

Josh Sandberg is the President of Ortho Spine Partners and Partner for The De Angelis Group. He also serves as Co-Founder and Editor of OrthoSpineNews.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button